Glucotrack Inc (GCTK) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Glucotrack Inc   (NASDAQ: GCTK)


Glucotrack Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Glucotrack Inc 's ROA in the second quarter of 2026?
Glucotrack Inc achieved a return on average assets (ROA) of 151.4 % in its second quarter of 2026, this is above GCTK's average return on assets of 35.49%.
Glucotrack Inc assets over the 12 months ending in its second quarter of 2026 are valued at $5 million

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 3 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 19, from total ROA ranking in the first quarter of 2026 at 26.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change -85.36 % -54.68 % 32.13 % 903.63 % 1579.28 %
Y / Y Net Income Change - -36.57 % -64.06 % -18.01 % 5.95 %
Net Income (TTM) in million 8 17 19 26 27
Return On Assets (TTM) 151.4 % 220.1 % 215.72 % 303.77 % 402.86 %
GCTK's Total Ranking # 19 # 26 # 23 # 16 # 15
Total Assets (TTM) in million 1 4 8 8 10
Seq. Total Assets Change -65.68 % -44.42 % -5.45 % -18.81 % 6.22 %
Seq. Net Income Change - 19.46 % -13.02 % -12.3 % -30.4 %

GCTK's 5 Years Annual ROA >> Back to GCTK Management Effectiveness >> Compare GCTK ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 1
Sector # 4
Overall # 20

Return On Assets Statistics
High Average Low
954.27 %
35.49 %
-1045.35 %
(Dec 31 2024)   (Sep 30 2018)



  News about Glucotrack Inc Return on Assets ROA

Glucotracks Strategic Reinforcement: Industry Veteran Peter C. Wulff Appointed CFO Amidst Financial Challenges

In a significant development for Glucotrack, the company has bolstered its executive leadership with the appointment of industry veteran Peter C. Wulff as the new Chief Financial Officer. This strategic move comes at a crucial time as Glucotrack seeks to enhance its financial strategy and accelerate the commercialization of its innovative continuous blood glucose monitor, specifically tailored for individuals managing diabetes.Wulff, who brings a wealth of experience and a proven track record in financial leadership, is expected to play a pivotal role in steering Glucotrack towards greater fiscal diligence and sustainability. His prior engagements have equipped him with the insights necessary to navigate the complexities of the healthcare technology landscape, ultimately positioning the company for growth amidst the competitive pressures inherent to the diabetes management sector.



Financial Statements
Glucotrack Inc 's Assets $ 1 million GCTK's Balance sheet
Glucotrack Inc 's Income $ -4 million Quarterly GCTK's Income Statement
GCTK's Income by Division See GCTK's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 32.13 % 20.94 % 101.19 % -61.09 % -40.93 %
Total Assets in million 8 6 5 2 6
Y / Y Net Income Change -14.2 % 218.4 % 60.02 % 9.05 % 50.85 %
Net Income in million 19 23 7 4 4
Annual Return On Assets 247.36 % 380.93 % 144.69 % 181.91 % 64.92 %

GCTK's 5 Years Annual ROA >> Back to GCTK Management Effectiveness >> Compare GCTK ROA to its Competitors



Comment on GCTK's ROA in the fiscal year ending 2025
In the fiscal year 2025 Glucotrack Inc 's ROA decreased compared to previous year to 247.36 %, due to deterioration of net income -14.2 % to $19.39 million, from $22.60 million a year ago, as GCTK's assets were $7.84 million.


More Return On Assets Ratios
GCTK's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GCTK's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GCTK's Competitors
Subscribers only: Roa for Glucotrack Inc 's Suppliers
Subscribers only: Return On Assets for GCTK's Customers

You may also want to know
GCTK's Roi GCTK's Inventory Turnover Ratio GCTK's Growth Rates GCTK's Dividend Comparisons
GCTK's Profitability Ratios GCTK's Asset Turnover Ratio GCTK's Dividend Growth
GCTK's Roe GCTK's Valuation Ratios GCTK's Financial Strength Ratios GCTK's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Kyntra Bio Inc   156.80 %
Vor Biopharma Inc   154.23 %
Glucotrack Inc   151.40 %
Capforce Inc   141.40 %
Protagenic Therapeutics Inc new  137.58 %
Elutia Inc   108.72 %
Silexion Therapeutics Corp  99.09 %
Arbutus Biopharma Corp  96.04 %
Pulmatrix Inc   94.81 %
Quince Therapeutics Inc   88.46 %
Interpace Biosciences Inc   85.91 %
Oncotelic Therapeutics Inc   81.75 %
Rigel Pharmaceuticals Inc  72.27 %
Actinium Pharmaceuticals Inc  71.73 %
Sanuwave Health Inc   71.60 %
Exelixis Inc   70.51 %
Rallybio Corporation  64.51 %
Oramed Pharmaceuticals Inc  64.18 %
Fortress Biotech Inc   60.88 %
Atlantic Coastal Acquisition Corp Ii  54.09 %
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %

Date modified: 2026-08-31T23:26:23+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.